Carnival Outlook Deemed Conservative and 3 Stock Analyses to Notice Now

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Medicines Co. (NASDAQ:MDCO): After the company announced positive results for the Phase III trial of Oritavancin, Leerink raised their price target for The Medicines Co. The firm believes that this positions The Medicines Co. as a partner and acquisition candidate. They reiterate an Outperform rating on the name.

Carnival Corporation (NYSE:CCL): Deutsche Bank believes that Carnival Corporation’s management is being overly conservative with their 2013 outlook. The firm recommends using any near-term share weakness as a buying opportunity and keeps a Buy rating on the stock with a $47 price target.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

American Reprographics Co. (NYSE:ARP): Atlas Resource Partners (NYSE:ARP) announced that the acquisition of certain DTE Energy (NYSE:DTE) assets include approximately 35 MMboe of proven reserves and substantial resource potential in the Fort Worth basin in Texas. This includes approximately a 75,000 net acres prospective for the oil and liquids rich Marble Falls play. The transaction represents American Reprographics Co.’s fourth acquisition since their creation last March for a total of approximately $700 million, thus bringing the company’s net pro forma proved reserves to approximately 900 Bcfe.

Arris Group Inc. (NASDAQ:ARRS): Needham sees more upside than downside from Arris Group Inc.’s synergy assumptions for their acquisition of Google’s Motorola Home business. The firm raised their price target for shares and keeps a Buy rating on the stock.

Don’t Miss: Here’s How Google is Making Advertisers Very Happy.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business